Impact of appropriate antimicrobial therapy on patient outcomes and antimicrobial use: a sub analysis of the DIANA Study Dataset
- Autori: José Pedro, C.; Pedro, P.; Pieter, D.; Sofie, D.; Ken, D.S.; Alexis, T.; Murat, A.; Menino Osbert, C.; Gennaro, D.P.; George, D.; Shigeki, F.; Jose, G.; Marc, L.; Jeffrey, L.; Marlies, O.; José-Artur, P.; Jeroen, S.; Fredrik, S.; Jean-François, T.; Jason A, R.; Jean Ralph, Z.; Farid, Z.; Kapil, Z.; Jan J, D.W.; Liesbet, D.B.; Rios, F.; Risso Vazquez, A.; Gabriela Vidal, M.; Zakalik, G.; George Attokaran, A.; Banakh, I.; Dey-Chatterjee, S.; Ewan, J.; Ferrier, J.; Forbes, L.; Fourie, C.; Leditschke, A.; Murray, L.; Eller, P.; Biston, P.; Bracke, S.; De Crop, L.; De Schryver, N.; Frans, E.; Spapen, H.; Van Malderen, C.; Vansteelandt, S.; Vermeiren, D.; Pablo Arévalo, E.; Crespo, M.; Zelaya Flores, R.; Píza, P.; Morocho Tutillo, D.; Elme, A.; Kallaste, A.; Starkopf, J.; Bourenne, J.; Calypso, M.; Cohen, Y.; Dahyot-Fizelier, C.; Depret, F.; Guillot, M.; Imzi, N.; Jochmans, S.; Kouatchet, A.; Lepape, A.; Martin, O.; Heim, M.; J Schaller, S.; Arvaniti, K.; Bekridelis, A.; Ioannidis, P.; Mitrakos, C.; N Papanikolaou, M.; Pouriki, S.; Vemvetsou, A.; Abraham, B.; Kumar Bhattacharya, P.; Budugu, A.; Dixit, S.; Gurav, S.; Kandanuri, P.; Arun Prabhu, D.; Rathod, D.; Savaru, K.; Neelavar Udupa, A.; Binu Varghese, S.; Haddad Bakhodaei, H.; Dabiri, G.; Javad Fallahi, M.; Feiz, F.; Firoozifar, M.; Khaloo, V.; Maghsudi, B.; Masjedi, M.; Nikandish, R.; Sabetian, G.; Marsh, B.; Martin-Loeches, I.; Steiner, J.; Barbagallo, M.; Caricato, A.; Cortegiani, A.; D'Andrea, R.; Deana, C.; Donati, A.; Girardis, M.; Mandalà, G.; Panarello, G.; Pasero, D.; Pelagalli, L.; Maurizio Soave, P.; Spadaro, S.; Fujita, Y.; Fujiwara, S.; Hara, Y.; Hashi, H.; Hashimoto, S.; Hashimoto, H.; Hayakawa, K.; Inoue, M.; Isokawa, S.; Kameda, S.; Kamohara, H.; Kanamoto, M.; Katayama, S.; Kawagishi, T.; Kawano, Y.; Kida, Y.; Kita, M.; Kobayashi, A.; Kuriyama, A.; Naito, T.; Nashiki, H.; Nishiyama, K.; Shindo, S.; Suzuki, T.; Takaba, A.; Tanaka, C.; Tetsuya, K.; Tomioka, Y.; Yanagawa, Y.; Yoshida, H.; Adnan, S.; Shahnaz Hasan, M.; Sulaiman, H.; A Gasca Lopez, G.; M Hernández-Cárdenas, C.; A Ñamendys-Silva, S.; Bethlehem, C.; De Lange, D.; Hunfeld, N.; Numan, S.; Van Leeuwen, H.; Owens, D.; Almeida, M.; Fragoso, E.; Leonor, T.; Pereira, J.; Filipescu, D.; Grigoras, I.; Popescu, M.; Tomescu, D.; S Alshahrani, M.; Alvarez-Gonzalez, M.; Barrero-García, I.; Angel Blasco-Navalpotro, M.; Claverias, L.; Estella, Á.; Forcelledo Espina, L.; Luis Garcia Garmendia, J.; García Prieto, E.; Gómez-Prieto, G.; Jiménez Conde, C.; Martinez Sagasti, F.; Muñoz Cantero, A.; Orejas-Gallego, A.; Papiol, E.; Pérez-Civantos, D.; Carlos Pozo Laderas, J.; Trenado Álvarez, J.; Vera-Artázcoz, P.; Vidal Cortés, P.; Oldner, A.; Spångfors, M.; Alp, E.; Köksal, I.; Korten, V.; Özveren, A.; Hall, A.; W Hatton, K.; Laudanski, K.; Desai, D.
- Anno di pubblicazione: 2026
- Tipologia: Articolo in rivista
- OA Link: http://hdl.handle.net/10447/708066
Abstract
Objective: Although inappropriate therapy has been consistently associated with adverse outcomes, the magnitude and consistency of the benefit associated with appropriate empiric therapy in critically ill patients remain uncertain. We aimed to quantify the prevalence of appropriate empiric antimicrobial therapy and evaluate its association with outcomes and antimicrobial exposure in a large international ICU cohort. Methods: This predefined sub-analysis of the DIANA study included adult ICU patients receiving empirical antimicrobials for suspected or confirmed bacterial infection. Only patients with microbiologically confirmed infections were analyzed, and therapy was classified as appropriate if at least one agent demonstrated in vitro activity against the identified pathogen. Associations with 28-day mortality and antimicrobial-free days were assessed using multivariable logistic and Cox regression models. Pre-specified interaction analyses explored effect modification by disease severity and diagnostic certainty. Results: Of 845 patients with microbiologically confirmed infections, 87.7% received appropriate empirical antimicrobial therapy. Compared with inappropriate therapy, appropriate therapy was associated with significantly lower ICU mortality and longer 28-day antimicrobial-free days and mechanical ventilation-free days. After multivariable adjustment, appropriate therapy remained independently associated with reduced 28-day mortality [adjusted odds ratio (OR) 1.83, 95% confidence interval 1.11-3.06, p = 0.02; hazard ratio (HR) 1.51, 95% CI 1.03-2.21, p = 0.035]. Effect-modification analyses demonstrated that the survival benefit of appropriate therapy was consistent across levels of diagnostic certainty and was most pronounced in patients with moderate illness severity (SOFA 3-9). Conclusion: In critically ill ICU patients, appropriate empirical antimicrobial therapy is independently associated with reduced 28-day mortality rates.